**Specifications Table**TableSubject areaPharmaceutical SciencesMore specific subject areaPhase I randomized clinical trial, first-time-in-humans, dose escalationType of dataTableHow data was acquiredClinical assessments and blood samplingData formatFilteredExperimental factorsThe trial was approved by the Medicine and Healthcare productsRegulatory Agency (MHRA). Participants (*N* = 80, total across the two experiments) are administered GET 73 either as single escalation dose \[10, 30, 100, 300, 450, or 600-mg) or a repeated dose (100, 300, 450, 450-mg (twice a day)\] over 14 daysExperimental featuresThis was a double-blind, placebo-controlled, ascending dose, Phase I randomized clinical trial conducted in healthy male volunteers in two Experiments. The primary aim was to look at the safety and tolerability of GET 73. In addition, preliminary pharmacokinetic data on GET 73 and its main metabolite MET 2 were collectedData source locationLCG Bioscience, Cambridge, UKData accessibilityThe data are available in this article

**Value of the data**•Data provides safe doses for administration of GET 73.•Data outlines the procedures tested for safe administration of GET 73 at safe doses in future study groups.•Pharmacokinetic parameters were collected for GET 73 and MET 2 as reference data to evaluate the bioavailability of GET 73.

1. Data {#s0005}
=======

The dataset presents an outline of the study and pharmacokinetic analytical data for GET 73: (N-\[4-(trifluoromethyl)benzyl\]-4-methoxybutyramide) (Haass-Koffler et al., 2017) [@bib1]. Pharmacokinetic data for MET 2: (4-oxo-4-{\[(4-trifluoromethyl)benzyl\]amino}butanoic acid), a main metabolite of GET 73, is also included in the data set. [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"} present procedural outlines for the Phase I randomized clinical trial. [Table 6](#t0030){ref-type="table"}, [Table 7](#t0035){ref-type="table"}, [Table 8](#t0040){ref-type="table"}, [Table 9](#t0045){ref-type="table"}, [Table 10](#t0050){ref-type="table"} provide pharmacokinetic data for GET 73, while [Table 11](#t0055){ref-type="table"}, [Table 12](#t0060){ref-type="table"}, [Table 13](#t0065){ref-type="table"}, [Table 14](#t0070){ref-type="table"} provide pharmacokinetic data for MET 2.Table 1*Experiment 1,* single ascending dose schedule.Table 1**PhaseScreeningInpatient periodStudy drug administrationOutpatient visitFollow-upDays**−21 to −2−1 to 31315Table 2*Experiment 2,* multiple ascending dose schedule.Table 2**PhaseScreeningInpatient periodStudy drug administrationOutpatient visitsResidency periodFollow-upDays**−21 to −2−1 to 31 to 145, 7, 9, 11, and 1313 to 1628Table 3*Experiment 1,* assessments and procedures.Table 3![](fx1.gif)Table 4*Experiment 2,* assessments and procedures.Table 4![](fx2.gif)Table 5Clinical laboratory assessments.Table 5**Clinical chemistryHaematology**γ Glutamyl TransferaseHaematocritAlanine TransaminaseHaemoglobinAspartate TransaminaseAlkaline PhosphataseMean Corpuscular HaemoglobinPotassiumSodiumMean Corpuscular Hemoglobin ConcentrationCalciumMean Cell VolumeBilirubin -- Direct (only if Total Bilirubin was outside the normal range)Platelet countBilirubin -- TotalRed Blood Cell countAlbuminUrinalysisProtein -- TotalpHWhite Blood Cell count (1)Leukocytes (2)CreatinineNitriteGlucose (fasting)GlucoseInorganic PhosphateKetonesTriglyceridesProtein (2)CholesterolBlood (2)UreaUrine test for drugs of abuseUric AcidAmphetaminesEcstasySerum virologyBarbituratesHepatitis B Core AntibodyBenzodiazepinesHepatitis B Surface AntigenCannabisHepatitis C VirusCocaineHIV-l / HIV-2MethadoneOpiates[^1]Table 6*Experiment 1,* GET 73 Pharmacokinetics parameters: *C*~*max*~ (ng/mL), *AUC*~*0-t*~ (ng\*h/mL) and *t*~*max*~ (h) by dose/treatment and day.Table 6Dose GET 73*C*~*max*~ (ng/mL)*AUC*~*0-t*~ (ng\*h/mL)*t*~*max*~ (h)10-mg48.35 (27.47--69.23)60.04 (25.97--94.11)0.50 (0.5--1.0)30-mg309.67 (211.46--407.88)387.36 (224.72--550.01)0.50 (0.50--1.02)100-mg721.33 (250.65--1192.01)1246.80 (690.63--1802.98)0.75 (0.50--1.50)300-mg1384.67 (510.79--2258.54)3624.01 (1451.26--5796.77)0.75 (0.50--1.50)450-mg3891.67 (2442.82--5340.52)6931.90 (3314.19--10,549.62)0.50 (0.50--1.00)600-mg5015.0 (3061.38--6968.62)13,338.25 (7495.02--19,181.48)0.75 (0.50--1.50)[^2]Table 7*Experiment 2,* GET 73 Pharmacokinetics parameters: *C*~*max*~ (ng/mL) by dose/treatment and day.Table 7Dose GET73Day 1 - single dose (ng/mL)Day 14 - repeated doses (ng/mL)100-mg368.17 (218.85--517.48)302.67 (151.32--454.02)300-mg2660.33 (1348.94--3971.73)2075.67 (1016.19--3135.14)450-mg3723.33 (2774.58--4672.08)3161.83 (2089.28--4234.39)450-mg twice day3271.67 (2140.81--4402.52)4055.00 (2587.33--5522.67)[^3]Table 8*Experiment 2,* GET 73 Pharmacokinetics parameters: *t*~*max*~ (h) by dose/treatment and day.Table 8Dose GET73Day 1 - single dose (h)Day 14 - repeated doses (h)100-mg1.00 (0.50--1.50)1.00 (0.50--1.50)300-mg0.50 (0.50--1.00)0.75 (0.50--1.50)450-mg1.00 (0.50--1.53)1.00 (0.50--1.50)450-mg twice day0.75 (0.5--2.05)0.75 (0.50--1.50)[^4]Table 9*Experiment 2,* GET 73 Pharmacokinetics parameters: *AUC*~*0-t*~ (ng\*h/mL) by dose/treatment and day.Table 9Dose GET73Day 1 - single dose (ng\*h/mL)Day 14 - repeated doses (ng\*h/mL)Ratio day 14/day1100-mg657.3 (382.67--931.59)598.75 (369.52--827.98)0.91300-mg6348.74 (2297.78--10,399.70)5938.89 (2193.79--9684.00)0.94450-mg8541.24 (6244.42--10,838.07)8102.90 (4724.25--11,481.55)0.95450-mg twice day8639.29 (5811.59--11,467.00)9704.90 (6053.12--13,356.68)1.12[^5]Table 10*Experiment 2,* GET 73 Pharmacokinetics parameters: *C*~*min*~ (ng/mL) by dose/treatment and day.Table 10Dose GET73Day 1 - single dose (ng/mL)Day 14 - repeated doses (ng/mL)100-mg0 (0--0)0 (0--0)300-mg0.36 (−0.35 to 1.07)0 (0--0)450-mg0.36 (−0.35 to 1.07)0 (0--0)450-mg twice day49.99 (−5.45 to 105.42)39.36(12.16--66.57)[^6]Table 11*Experiment 2,* MET 2 parameters: *C*~*max*~ (ng/mL) by dose/treatment and day.Table 11Dose GET73Day 1 -single dose (ng/mL)Day 14 - repeated doses (ng/mL)100-mg1728.33 (1415.98--2040.68)1491.33 (1042.06--1940.61)300-mg4193.33 (3550.43--4836.23)4511.67 (3828.91--5194.42)450-mg6691.67 (5304.95--8078.38)6003.33 (5664.54--6342.12)450-mg twice day7406.67 (6299.63--8513.71)8820.00 (7482.47--10,157.53)[^7]Table 12*Experiment 2,* MET 2 parameters: *t*~*max*~ (h) by dose/treatment and day.Table 12Dose GET73Day 1 - single dose (h)Day 14 - repeated doses (h)100-mg1.00 (0.50--1.50)1.00 (0.50--1.50)300-mg1.00 (0.50--1.50)1.50 (1.00--2.00)450-mg1.25 (1.00--2.00)1.25 (1.00--1.50)450-mg twice day1.25 (1.05--2.05)1.29 (1.00--1.60)[^8]Table 13*Experiment 2,* MET 2 parameters: *AUC*~*0-t*~ (ng\*h/mL) by dose/treatment and day.Table 13Dose GET73Day 1 - single dose (ng\*h/mL)Day 14 - repeated doses (ng\*h/mL)Ratio day 14/day1100-mg3934.30 (3373.35--4495.25)3790.54 (3086.52 - 4494.56)0.96300-mg15,235.13 (11,392.92--19,077.34)15,312.29 (11,615.23 - 19,009.35)1.00450-mg21,051.64 (18,233.17--23,870.10)20,693.28 (19,477.42 - 21,909.14)0.98450-mg twice day30,443.09 (24,553.06--36,333.12)32,251.41 (26,029.38 - 38,473.43)1.06[^9]Table 14*Experiment 2,* MET 2 Pharmacokinetic parameters: *C*~*min*~ (ng/mL) by dose/treatment and day.Table 14Dose GET73Day 1 - single dose (ng/mL)Day 14 - repeated doses (ng/mL)100-mg0 (0--0)0 (0--0)300-mg0 (0--0)0 (0 to 0)450-mg0 (0--0)0 (0--0)450-mg twice day804.43 (−240.21 to 1849.08)426.58 (85.56--767.71)[^10]

In [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, timetables were set for the administration of GET 73 and the collection of data for the safety and tolerability of GET 73 in single and repeated ascending doses in healthy male volunteers.

In [Tables 3 and 4](#t0020){ref-type="table"}, a procedure was documented for both single and repeated ascending doses with the goal of collecting preliminary pharmacokinetic data and monitor the safety of participants.

[Table 5](#t0025){ref-type="table"} lists laboratory assessments for safety of GET 73 and potential factors that can affect its tolerability. Some tests were also used for inclusion/exclusion criteria (urine tests for drugs of abuse).

[Table 6](#t0030){ref-type="table"} data shows the extent of exposure of GET 73 plasma concentration in a single ascending dose. *C*~*max*~ and *AUC*~*0-t*~ are measures of these factors respectively with *t*~*max*~ as a reference to the maximum concentration of GET 73 in the plasma.

[Table 7](#t0035){ref-type="table"} tests for *C*~*max*~ in repeated ascending dose administration with data for Day 1 and Day 14.

For [Table 8](#t0040){ref-type="table"}, *t*~*max*~ was collected in reference to when the *C*~*max*~ was reached in the repeated ascending dose administration group for both Day 1 and Day 14.

[Table 9](#t0045){ref-type="table"} measures the *AUC*~*0-t*~ for repeated ascending dose administration experiment. *AUC*~*0-t*~ ratio compares Day 14 to Day 1 levels.

[Table 10](#t0050){ref-type="table"} shows the *C*~*min*~ of GET 73 in the plasma over the repeated ascending dose administration. Data reported for Day 1 and Day 14.

[Table 11](#t0055){ref-type="table"} goes into data about MET 2, the main metabolite of GET 73. Data reported for Day 1 and Day 14.

[Table 12](#t0060){ref-type="table"} shows the *t*~*max*~ of MET 2 in the repeated ascending dose administration of GET 73.

Data reported for Day 1 and Day 14.

[Table 13](#t0065){ref-type="table"} collects data on the *AUC*~*0-t*~ of MET 2 in the plasma after repeated ascending dose administration of GET 73. Ratio compares Day 14 and Day 1 data are listed as well.

[Table 14](#t0070){ref-type="table"} measures the *C*~*min*~ of MET 2 in the plasma for repeated ascending dose administration of GET 73. Data was collected for Day 14 and Day

2. Experimental design, materials and methods {#s0010}
=============================================

The method for collection of pharmacokinetic analytical data was validated at Quotient Bioresearch Ltd, UK. The procedures for the development and the validation of the method were based on the United States (US) Food and Drug Administration (FDA) recommendations Guidance for Industry Bioanalytical Method Validation - U.S. Department of Health and Human Services, FDA Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), May 2001, BP.

Blood samples for pharmacokinetic evaluation in plasma were collected into tubes containing lithium heparin prior to dosing and at various time points after dosing up to 48 h for *Experiment 1* and up to 360 h for *Experiment* *2*. The plasma samples were obtained from individuals from six single ascending dose groups in *Experiment 1* (10-mg, 30-mg, 100-mg, 300-mg, 450-mg and 600-mg) and four multiple ascending dose groups in *Experiment 2* (100-mg 300-mg, 450-mg and 450-mg twice a day).

Concentrations of GET 73 in human plasma samples were measured by LC--MS/MS after SLE+ (supported liquid extraction) over the calibration range of 2--1000 ng/ml according to the validated method and the relevant SOPs. Concentrations of MET 2 in human plasma samples were measured by LC--MS/MS after protein precipitation and dilution over the calibration range of 20--10,000 ng/ml. All instrument control, data collection, peak area integration and storage were performed using Analyst (versions 1.4.2 and 1.5.1, Applied Biosystems Inc., OA, US). Peak areas were then imported into Watson LIMS (version 7.2 Thermo Fisher Scientific Inc., MA, US) for regression and quantification. The mass spectrometer response (peak area ratio of analyte to internal standard) of each calibration standard was calculated by Watson LIMS and plotted against the nominal (prepared) concentration. A weighted linear regression analysis was used to calculate an equation of the calibration line. Concentrations of GET 73 and MET 2 in the plasma samples were back calculated from the calibration lines.

Values for the following pharmacokinetic parameters were estimated: 1) maximum plasma concentration (*C*~*max*~), 2) the time to reach maximum plasma concentration (*t*~*max*~) and 3) the area under the plasma concentration time curve over the dosing interval (*AUC*~*(0-t)*~). Pharmacokinetic parameters were derived by noncompartmental analysis using WinNonlin (Version 4.1b, Pharshight Corporation, Mountain View, CA, US). Data in this article has not been published elsewhere.
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[^1]: 1 White blood cell count included differential white blood cell count. 2 Direct microscopy was performed if the sample was positive for any of these parameters.

[^2]: Results reported as *M* and lower to upper 95% (*CI*) and for *t*~*max*~ as median (min-max values).

[^3]: Results reported as *M* and lower to upper 95% (*CI*).

[^4]: Results reported as *Median* and minimum and maximum.

[^5]: Results reported as *M* and lower to upper 95% (*CI*).

[^6]: Results reported as *M* and lower to upper 95% (*CI*).

[^7]: Results reported as *M* and lower to upper 95% (*CI*).

[^8]: Results reported as *Median* and minimum and maximum.

[^9]: Results reported as *M* and lower to upper 95% (*CI*).

[^10]: Results reported as *M* and lower to upper 95% (*CI*).
